2.00

0.99% -0.02

After Hours: 2.00

Alterity Therapeutics Ltd ADR (ATHE)

Overview News Price History Discussions Forecast Stock Split

Alterity Therapeutics Ltd ADR stock is currently priced at $2.00, with a 24-hour trading volume of 15,230. It has seen a -0.99% decreased in the last 24 hours and a -0.50% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.04 pivot point. If it approaches the $1.95 support level, significant changes may occur.

Previous Close:

$2.02

Open:

$1.99

24h Volume:

15,230

Market Cap:

$17.46M

Revenue:

Net Income/Loss:

P/E Ratio:

-2.8201

EPS:

-0.7092

Net Cash Flow:

1W Performance:

-0.50%

1M Performance:

-0.50%

6M Performance:

-15.97%

1Y Performance:

-31.03%

1D Range:

$1.93

$2.0292

52W Range:

$1.55

$5.41

Alterity Therapeutics Ltd ADR Stock (ATHE) Company Profile

Name

Alterity Therapeutics Ltd ADR

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

61 3 9349 4906

Address

460 Bourke Street, Level 3, Melbourne, VIC

Employee

Twitter

@AlterityT

Next Earnings Date

Latest SEC Filings

ATHE's Discussions on Twitter

Alterity Therapeutics Ltd ADR Stock (ATHE) Latest News

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

GlobeNewswire Inc.

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

GlobeNewswire Inc.

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia

GlobeNewswire Inc.

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

GlobeNewswire Inc.

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

GlobeNewswire Inc.

Alterity Therapeutics Ltd ADR Stock (ATHE) Financials Data

There is no financial data for Alterity Therapeutics Ltd ADR (ATHE). Check out other stocks for more information.

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.